Learn About Treatment Options for Rheumatoid Arthritis: A Clinical Overview

Learn About Treatment Options for Rheumatoid Arthritis through a structured review of the medicines, rehabilitation approaches, lifestyle measures, monitoring practices, and surgical options used in contemporary care. Rheumatoid arthritis is a chronic autoimmune disease that can damage joints and affect other organs, so treatment generally combines disease control with symptom management and functional support. 1

Goals and principles of rheumatoid arthritis treatment

The central goals of rheumatoid arthritis treatment are to reduce pain and stiffness, slow or stop disease progression, prevent joint damage, improve physical function, and reduce fatigue and weakness. Because inflammation can progressively damage cartilage, bone, tendons, and ligaments, treatment is intended to address the underlying disease rather than pain alone. A rheumatologist typically develops an individualized plan based on symptoms, disease activity, other health conditions, and response to therapy. 1

Early, intensive treatment is associated with a greater likelihood of remission or low disease activity. Treatment progress may be assessed through symptoms, physical examination, blood tests, and disease-activity scores, with follow-up sometimes occurring monthly or every two to three months depending on the disease stage and medicines used. Medication adjustments are therefore a normal part of long-term care rather than evidence that treatment has failed. 6

Conventional disease-modifying antirheumatic drugs

Disease-modifying antirheumatic drugs, commonly called DMARDs, are the main medicines used to slow rheumatoid arthritis and reduce the risk of structural joint damage. Conventional synthetic DMARDs include methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine. Methotrexate is often the first medicine prescribed, although two or more conventional DMARDs may be combined when a single medicine does not sufficiently control disease activity. 1

DMARDs differ in administration, expected effects, interactions, and monitoring requirements. Clinical surveillance can include laboratory testing, vaccination planning, and ophthalmologic screening for selected medicines. Treatment selection also requires consideration of pregnancy, kidney or liver impairment, infection risk, and other medical conditions. These factors make prescribing and dose changes decisions for a qualified clinician, not self-directed adjustments. 9

Biologic and targeted synthetic therapies

Biologic DMARDs are genetically engineered proteins designed to target specific immune-system components that drive inflammation. They are commonly considered when rheumatoid arthritis does not respond adequately to conventional DMARDs. Different biologics act through different inflammatory pathways, and a person who does not respond to one biologic may respond to another. These medicines are administered by injection or infusion, creating practical considerations for storage, scheduling, administration, and infection monitoring. 1

Janus kinase, or JAK, inhibitors are targeted synthetic DMARDs taken orally. They interfere with intracellular enzymes involved in inflammatory signaling, including Janus kinase pathways. Like other immune-modifying treatments, JAK inhibitors require assessment of medical history, concurrent medicines, laboratory results, and potential safety concerns. The choice between conventional, biologic, and targeted synthetic DMARDs depends on disease activity, previous treatment response, risks, preferences, and clinical guidance. 9

Medicines for pain and short-term inflammation

Nonsteroidal anti-inflammatory drugs, or NSAIDs, can reduce pain, stiffness, and inflammation, but they do not prevent rheumatoid arthritis from progressing or repair existing joint damage. They may be used alongside a DMARD, particularly while disease-modifying treatment is taking effect. Prescription-strength doses can provide greater anti-inflammatory action, but the appropriate dose and duration depend on individual cardiovascular, kidney, gastrointestinal, and blood-pressure risks. 1

Long-term or high-dose NSAID use can be associated with ulcers, gastrointestinal bleeding, fluid retention, impaired kidney function, high blood pressure, and increased risk of heart attack or stroke. Corticosteroids can provide rapid relief from inflammation and pain, but they are generally used for short-term management because extended exposure can create significant health risks. Clinicians may also use protective gastrointestinal medicines for selected people who require longer NSAID treatment. 5

Physical therapy, occupational therapy, and lifestyle measures

Physical therapy can help preserve joint movement, strengthen muscles around affected joints, and support functional capacity. Occupational therapy focuses on practical methods for performing daily tasks with less stress on painful or weakened joints. Splinting and other physical measures may also be included. These approaches complement medication by addressing mobility, independence, fatigue management, and the ability to perform ordinary activities. 7

Regular low-impact physical activity, maintaining a healthy weight, stopping smoking, and following a generally healthy lifestyle are commonly included in comprehensive rheumatoid arthritis management. Smoking is linked with rheumatoid arthritis risk and may interfere with medication effectiveness. Lifestyle measures do not replace DMARD therapy, but they can support physical function and overall disease management when adapted to symptoms and personal capacity. 1

Surgery, monitoring, and long-term safety

Surgery may be considered when severe joint destruction, persistent pain, deformity, or loss of function remains despite medical treatment. Procedures can include repair or fusion of damaged joints and joint replacement, also called arthroplasty. Surgical decisions depend on the affected joint, structural damage, functional limitations, general health, and expected rehabilitation needs. Surgery addresses mechanical damage, while DMARD treatment remains important for controlling the systemic inflammatory disease. 4

Rheumatoid arthritis is a long-term condition that may require continuing medication even after remission or low disease activity is achieved. Ongoing care commonly includes review of symptoms, examination, laboratory monitoring, medication safety assessment, and evaluation of treatment response. Tapering or discontinuing a DMARD is a specialized decision addressed in updated clinical guidance and may carry a risk of renewed disease activity, so it should not be undertaken without rheumatology supervision. 5

Sources

1. Arthritis Foundation, Treatments for Rheumatoid Arthritis
2. Harvard Health, Rheumatoid Arthritis: An Overview
3. Penn Medicine, Rheumatoid Arthritis
4. Merck Manual Professional Edition, Rheumatoid Arthritis
5. Journal of Rheumatology, Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis
6. Sharecare, Rheumatoid Arthritis: Treatment and Remission
7. Merck Manual Consumer Version, Rheumatoid Arthritis
8. MSD Manual Consumer Version, Rheumatoid Arthritis
9. NCBI Bookshelf, Disease-Modifying Antirheumatic Drugs